Clik here to view.
Study: Industry funding biases drug trials in favor of sponsors
Researchers from the University of Sydney published a review this week, concluding that industry-funded drug trials are often biased in favor of the sponsors’ products. According to Lisa Bero of the...
View ArticleClik here to view.
FDA accepts Ocular’s NDA resubmission for Dextenza
Ocular Therapeutix (NSDQ:OCUL) said today that the FDA accepted the company’s resubmitted New Drug Application for its post-surgical ocular pain reliever, Dextenza. The hydrogel plug, inserted into a...
View ArticleClik here to view.
Meril’s bioresorbable, drug-eluting vascular scaffold
Meril Life Sciences has developed a drug-eluting, bioresorbable vascular scaffold that the body can slowly degrade and wash away. The company’s MeRes100 is made of biodegradable polymers, PLLA and...
View ArticleClik here to view.
Amgen wins marketing authorization for Repatha single-dose delivery option
Amgen (NSDQ:AMGN) said today that the European Commission granted a change to the marketing authorization of its Repatha device, approving a single-dose delivery option. The pre-filled cartridge...
View ArticleClik here to view.
GlaxoSmithKline, Innoviva tout data for Relvar Ellipta inhaled drug combo
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) touted data today from a non-inferiority lung function study evaluating its inhaled, once-daily corticosteroid/long-acting beta2 agonist combination...
View ArticleClik here to view.
Children’s National Health System highlights novel approach for cell therapy
Children’s National Health System touted data today from a Phase I dose-ranging study evaluating a cell therapy approach in patients with blood and bone marrow cancers for whom stem cell...
View ArticleClik here to view.
Bristol-Myers prices $1.5B senior notes offering
Bristol-Myers Squibb (NYSE:BMY) said today that it has agreed to sell $1.5 billion of senior unsecured notes in an underwritten public offering. The offering includes $750 million in 1.6% senior notes...
View ArticleClik here to view.
Study: Nanotechnology could cut dose of HIV treatment in half
Researchers from the University of Liverpool presented data this week evaluating the use of nanotechnology to improve drug therapies for HIV patients. The team touted its data at the Conference on...
View ArticleClik here to view.
Report finds pharma companies limited January list price hikes
Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although...
View ArticleClik here to view.
Aerie resubmits NDA for Rhopressa eye drops
Aerie Pharmaceuticals (NSDQ:AERI) said today that it resubmit a New Drug Application for the company’s Rhopressa eye drops. The Irvine, Calif.-based company’s NDA was withdrawn in October last year,...
View ArticleClik here to view.
Study: Patient error cuts dose in half for inhalers
Researchers from Rice University and Baylor College of Medicine have identified patient errors that cause inhaler users to get about half as much medicine as they should from each dose. The team said...
View ArticleClik here to view.
EnGeneIC wins orphan drug designation for targeted nanocells
EnGeneIC said today that the FDA granted orphan drug designation to the company’s targeted EDV nanocells for the treatment of glioblastoma multiforme. The clinical stage biopharmaceutical company is...
View ArticleClik here to view.
DoD taps BD’s Pyxis for $100m medication dispensing contract
Becton Dickinson & Co. (NYSE:BDX) said today that it won a $100 million contract from the U.S. Department of Defense for its Pyxis ES system. According to the contract, Franklin Lakes, N.J.-based...
View ArticleClik here to view.
Valerion develops antibody delivery method for Pompe disease therapy
Valerion Therapeutics said today that the company developed a fusion protein, VAL-1221, that combines its antibody delivery system with recombinant human acid alpha-glucosidase (rhGAA) to better...
View ArticleClik here to view.
Study: Growing concern over narcotic painkillers and their addiction risk
More than 50% of Americans have been prescribed narcotic painkillers, according to a Truven Health Analytics-NPR Health poll, and more than one third of respondents were concerned about painkillers’...
View ArticleClik here to view.
AcelRx Pharmaceuticals gains on Q4 earnings
Shares in AcelRx Pharmaceuticals (NSDQ:ACRX) rose today after the pharmaceutical company met expectations on Wall Street with its 4th quarter results. The Redwood City, Calif.-based company pared its...
View ArticleClik here to view.
Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution
Mast Therapeutics (NYSE:MSTX) said today that its subsidiary Aires Pharmaceuticals inked a deal with the University of Pittsburgh related to its phase 1/2 open-label proof-of-concept trial for the...
View ArticleClik here to view.
BTG wins CE Mark for DC Bead Lumi radiopaque drug-eluting bead
BTG (LON:BTG) said today that it won CE Mark clearance in the European Union for its DC Bead Lumi radiopaque drug-eluting bead. The bead is designed to be loaded with doxorubicin or irinotecan to...
View ArticleClik here to view.
Demand for EpiPen alternatives jumps as states consider access legislation
Prescriptions for EpiPen alternatives such as Kaléo Inc.‘s Auvi-Q device have quadrupled since the beginning of this year, according to data from the Athenahealth Network. The demand for cheaper...
View ArticleClik here to view.
Opioid treatment implant-maker Braeburn secretly funded advocacy group...
Opioid treatment implant-maker Braeburn Pharmaceuticals said in a regulatory filing last month that it has made charitable donations to an advocacy group fronted by Newt Gingrich and Patrick Kennedy...
View Article